|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Dear Reader, Thank you for your continued support and encouragement. Please note: As is our custom, we are taking a short summer break and will be back in September with our monthly updates. Take care, enjoy the summer. See you in September. Affymetrix Inc. intends to acquire ParAllele BioScience Inc. for $120 million in stock. ParAllele's multiplexing Molecular Inversion Probe test will be combined with Affymetrix' GeneChip universal tag system. The acquisition is expected to close in the third quarter of 2005. AcroMetrix Corporation acquired the rights to manufacture quality control products incorporating Ambion Diagnostics', a division of Ambion, Inc., Armored Technology. Applied Imaging Corp. received FDA clearance to market its Ariol Her-2/neu FISH. The test is part of a menu that assays for Her-2/neu Immunohistochemistry (IHC), Her-2/neu FISH, Estrogen Receptor, and Progesterone Receptor. Bayer HealthCare LLC, Diagnostics Division acquired an exclusive worldwide license for EraGen Biosciences' MultiCode-PLx System to develop a rapid, automated tests for CF mutation carrier screening and for neonatal and newborn testing. The agreement also provides Bayer HealthCare with additional rights for assays for other disease states. Cangen Biotechnologies, Inc. entered into a collaboration with Olympus Corporation for the development of a hybrid DNA-based and protein-based diagnostic test for use in the detection of lung cancer based on Olympus' microarray technology. Digene Corp. acquired a non-exclusive license to Luminex's xMAP bead technology for use in women's in cervical cancer screening tests and women's health diagnostics. Genzyme Corp. entered into an exclusive agreement with Massachusetts General Hospital and the Dana-Farber Cancer Institute to develop a epidermal growth factor receptor, or EGFR gene test that can be used to identify patients who are most likely to respond to EGFR targeted therapies, including the Iressa (AstraZeneca PLC) and Tarceva (OSI Pharmaceuticals). QIAGEN N.V. plans to acquire artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH. The artus RealArt assays have been developed for use on the major thermal cycling platforms and electrophoresis detection systems. Roche Diagnostics and 454 Life Sciences, a subsidiary of CuraGen Corporation entered into an exclusive 5-year world-wide agreement for the development, promotion, sale, and distribution of 454 Life Sciences' nanotechnology-based Genome Sequencing Systems, kits and reagents. The 454 Life Sciences' technology allows a instrument to produce over 20 million nucleotide bases per four hour run. Tm Bioscience received FDA clearance to market its Tag-It Cystic Fibrosis kit. This is the first FDA-cleared genetic disease test using Luminex's xMAP multiplexing technology and is also the first FDA cleared test for Cystic Fibrosis. TriPath Imaging, Inc. and Ventana Medical Systems, Inc. received FDA clearance to market the Ventana Image Analysis System (VIAS) when used with tissues stained for Estrogen Receptor and Progesterone Receptor. Ventana entered into a global agreement to market Ventana-branded products on the TriPath system.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: June 6, 2005 |
![[Page Banner Image]](images/hmole.gif){kind=small}
